Nirmatrelvir/Ritonavir

Two familiar leaders—Eli Lilly (+45%) and Novo Nordisk (+30%)—paced an industry revenue boom in the fourth quarter. So far, Teva is the only drugmaker that posted a year-over-year sales decline in the fourth quarter. Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. Of the world’s 22 biopharma companies that had reported quarterly revenue of at least $2 billion by Feb. 24, only one posted a year-over-year decline.And that decrease had a caveat. Teva saw its revenue fall by 5% in the fourth quarter because of a $500 million upfront payment it received in a drug collaboration with Sanofi in the fourth quarter of 2023. Without that addition, which the company chalked up as revenue, Teva would have reported a 5% increase in the most recent period.How rare is it to see a quarter in which just one biopharma had a revenue decline? Consider that in the first quarter of 2024, seven companies reported falling sales year-over-year.“Q4 is always tricky,” Pankit Bhalodia, West Monroe's managing director of healthcare and life sciences, said in an interview. “I don’t know how much of this is in anticipation of all the changes that might potentially happen in ’25 with the new [Trump] administration, with increased demand or whatnot.” The revenue increase leaders of the fourth quarter were familiar—Eli Lilly (45%) and Novo Nordisk (30%). For both companies, the increases were their highest for any quarter in 2024. While Lilly has delivered seven straight quarters with at least a 20% increase, Novo has topped the 20% growth mark in 12 consecutive quarters.Boosted by hefty sales of its diabetes and obesity drugs, Lilly posted an annual revenue increase of 32% in 2024, while Novo, with a similar growth portfolio, generated a 26% revenue bump for the year. Lilly’s revenue increase in the quarter wasn’t just due to its GLP-1/GIP products, however. The company also said that sales of its non-incretin drugs jumped by 20% year over year and pointed to the performance of breast cancer therapy Verzenio and heart failure treatment Jardiance, which rang up quarterly figures of $1.6 billion and $1.2 billion, respectively.Since announcing in January at the J.P. Morgan Healthcare Conference that it expects revenue to increase 32% in 2025, Lilly has seen its market cap increase from $745 billion to $844 billion, which is more than twice the value of any other company in the industry.Much of the investor enthusiasm surrounds the prospects of Lilly’s obesity treatments in a market that is still growing. Asked during the company’s quarterly conference call whether Lilly was reaching the “edge of the demand curve” for obesity drugs, CEO David Ricks said, “We don’t think we’re close to it right now.”“There’s a lot of potential growth in the GLP area—in other potential indications and other disease states,” Steven Lupo, also of consulting firm West Monroe, added in an interview.In presenting its quarterly earnings, Novo projected a slowdown in its sales momentum, estimating revenue will increase between 16% and 24% in 2025. Since that announcement, Novo’s market cap has increased slightly to $349 billion. With its surge over the last few years, Novo has become the highest valued biopharma company in Europe.Other double-digit gainers Of the 22 biopharma companies that reported fourth quarter revenue of more than $2 billion by Feb. 24, nine posted double-digit increases and nine others had single-digit increases of at least 5%.Among those with double-digit growth in the fourth quarter was AstraZeneca, with a 24% revenue increase, sparked largely by 27% increases in sales for both its oncology drugs and its respiratory and immunologic treatments. The showing in the quarter closed a remarkable year for the company in which its sales increased by 18%. AZ expects a slowdown in its momentum in 2025, projecting a revenue increase in the high single digits.Pfizer started the year with a 19% revenue decline in the first quarter, then ended it with a 23% sales increase in the fourth quarter. While the acquisition of Seagen—and the nearly $1 billion quarterly increase in sales of antibody-drug conjugate drugs brought by the Seattle biotech—played a significant role in boosting revenues, a larger factor was a surprising spike in the combined sales of COVID-19 products Comirnaty and Paxlovid, which reached $4.1 billion in the fourth quarter.While Astellas achieved a 22% quarterly revenue increase—due largely to booming sales of its Pfizer-partnered prostate cancer treatment Xtandi and ADC bladder cancer drug Padcev—there also was bad news. Due largely to the struggles of eye disease drug Syfovre and myotonic dystrophy gene therapy prospect AT466, Astellas wrote off impairments of 180 billion Japanese yen ($1.2 billion).Vertex and Novartis achieved revenue increases of 15% each in the fourth quarter, which was the highest quarterly increase either company achieved in 2024.For Novartis, a series of divestments have left it as a pure-play innovator better equipped to take advantage of its strengths, according to CEO Vas Narasimhan.“The strategy of focusing the company has unlocked value and actually enabled Novartis to be much stronger for the long run,” he told reporters last month.Other drugmakers with double-digit revenue increases were Amgen and Regeneron at 11% each. Amgen’s revenue bump was down from at least 20% in each of the other quarters of 2024 as the company realized added sales from its $27.8 billion acquisition of Horizon, which came complete early in the fourth quarter of 2023.While Regeneron is struggling to make advances with its Eylea franchise, it is thriving with Sanofi-partnered Dupixent—which gained a key FDA nod to treat chronic obstructive pulmonary disease last year—and cancer treatment Libtayo, which reached blockbuster sales for the first time in 2024.Single-digit gainers It was a successful quarter for several drugmakers that saw single-digit revenue gains, including AbbVie (6%), which had its highest quarterly revenue increase since the fourth quarter of 2021. The performance is evidence that the company has come full circle from the loss of exclusivity of megablockbuster Humira and that its next-gen immunology duo Skyrizi and Rinvoq is primed to provide growth over the next decade. In its fourth-quarter earnings presentation, AbbVie estimated combined sales of the Humira follow-ons would reach $31 billion in 2027.Gilead Sciences saw a revenue increase of 6% in the quarter, continuing its momentum for the year. In 2024 overall, fueled by sales of HIV products, Gilead had a 6% bump in sales, which came after small revenue declines in the previous two years. The company expects a reversion in 2025, with sales falling from $28.8 billion to a range of $ billion to $28.6 billion.Johnson & Johnson had a modest 5% increase in the fourth quarter, but the company is making steady progress with its sales gains increasing in each quarter of 2024 as it rebuilds its revenue after spinning off its huge consumer health business. The new company, Kenvue, reported sales of $15.1 billion in 2024, which represented a 0.1% increase from the previous year, showing why J&J was anxious to shed the unit. For the purposes of these growth rankings, consumer healthcare companies like Kenvue are excluded. Another company that has undergone a recent reorganization—including an ongoing attempt to separate from its consumer health unit—is Sanofi. The French drugmaker closed a strong year with a 9% revenue increase in the fourth quarter.Bristol Myers Squibb also finished up a solid year with an 7% revenue gain in the fourth quarter, after increases of 9% and 8% in the previous two periods, though the bigger news during its fourth-quarter presentation was that the company will cut another $2 billion in costs by the end of 2027. BMS expects the sales momentum to halt next year, projecting revenue to decline from $48.3 billion to $45.5 billion this year.Biogen generated a 3% increase in sales in the fourth quarter, which was a promising turn-the-corner result considering that the company’s revenue has declined in each of the last four years, including a 2% drop in 2024.Disappointments A few drugmakers reported disappointing results in the fourth quarter. One was GSK, with a 1% increase as sales of Arexvy plummeted (PDF) by 70% year over year, largely because the Centers for Disease Control and Prevention narrowed its guidance on which adults should receive respiratory syncytial virus shots.For other companies that rely heavily on manufacturing vaccines—such as Merck, Sanofi, Pfizer and Moderna—there is considerable angst over what may become of the U.S. market with anti-vaccine activist Robert F. Kennedy Jr. taking over as secretary of the Department of Health and Human Services.“From a regulatory pathway and approval process—that’s probably one of the bigger concerns that I’m hearing,” Lupo said. “How will this effect what we’ve got in the pipeline? And when can we anticipate getting new products on the market?”  After double-digit revenue increases in each of the previous three quarters of 2024, Takeda saw just a 3% sales increase in its last quarter. A few drugmakers not included in this summary—which will present fourth-quarter earnings in the next few weeks—are likely to report revenue decreases. They include Bayer and Viatris, which each had sales decreases in each of the first three quarters of 2024. Additionally, Merck KGaA, which has yet to report, entered the fourth quarter with a 1% revenue decline through the first nine months of 2024.

On Track to Report Topline Results for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in 3Q 2025 Advancing Immunology Portfolio with Ongoing IND Enabling Studies of KIT Inhibitor EPS-1421 On Track to Announce STAT6 Development Candidate in 2H 2025 Operations Supported by Cash and Marketable Securities Totaling $216.7 Million at December 31, 2024 , as well as Continuing Retained Royalties WATERTOWN, Mass. --(BUSINESS WIRE)--Feb. 10, 2025-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal first quarter ended December 31, 2024 . “2025 is primed to be a pivotal year for Enanta as we execute on multiple catalysts across our pipeline, including progression of our RSV compounds and expansion of our immunology portfolio. Recruitment for RSVHR, our Phase 2 study of zelicapavir in high-risk adults infected with RSV, is ongoing and we plan to report topline data in the third quarter of this year. Following the encouraging results from our pediatric RSV study, we look forward to working with regulators to align on the registration pathway for zelicapavir in children and await the results of RSVHR, a Phase 3 enabling trial for adults. With both zelicapavir and EDP-323, we have the leading portfolio of RSV candidates in clinical development today and are eager to develop potential first-in-disease and best-in-class treatments for patients suffering from RSV,” said Jay R. Luly , Ph.D., President and Chief Executive Officer at Enanta Pharmaceuticals . “Moving forward, we will be exploring potential partnership opportunities to advance our RSV program. Simultaneously, we are working to ensure readiness for the next phase of RSV clinical development in a strategic and capital efficient manner, thereby extending our cash runway into fiscal 2028.” Dr. Luly added, “In parallel, we are rapidly advancing and expanding our immunology portfolio targeting Type 2 immune diseases, with an initial focus on indications with fast proof-of-concept. We are making progress to advance EPS-1421, our lead candidate for our KIT inhibition program, with the goal of developing a best-in-class, oral treatment for chronic spontaneous urticaria and other mast cell driven diseases. We are also excited about the progress in our STAT6 program, where we are leveraging our expertise in medicinal chemistry to develop novel, potent and selective oral inhibitors that block the IL-4/IL-13 signaling pathway, with an initial indication in atopic dermatitis and future expansion opportunities in asthma and other diseases. We expect to select a lead development candidate for STAT6 in the second half of this year and look forward to continuing to build out our immunology portfolio with the announcement of a third program this year. We have a busy year ahead with multiple opportunities to drive value for the company and move us closer to bringing important treatments to patients in need.” Fiscal First Quarter Ended December 31, 2024 Financial Results Total revenue for the three months ended December 31, 2024 was $17.0 million and consisted of royalty revenue from worldwide net sales of MAVYRET®/MAVIRET®, AbbVie’s eight-week treatment for chronic hepatitis C virus, compared to $18.0 million for the three months ended December 31, 2023 . The decrease in revenue is due to a decline in AbbVie’s sales of MAVYRET®/MAVIRET®. A portion (54.5%) of Enanta’s ongoing royalty revenue from AbbVie’s net sales of MAVYRET®/MAVIRET® is paid to OMERS, one of Canada’s largest defined benefit pension plans, pursuant to a royalty sale transaction affecting royalties earned after June 2023 . For financial reporting purposes, the transaction was treated as debt, with the upfront purchase payment of $200.0 million recorded as a liability. Each quarter, Enanta records 100% of the royalty earned as revenue and then amortizes the debt liability proportionally as 54.5% of the cash royalty payments are paid to OMERS through June 30, 2032 . This is subject to a cap of 1.42 times the purchase payment, after which point 100% of the cash royalty payments will be retained by Enanta. Interest expense was $2.0 million for the three months ended December 31, 2024 , as compared to interest expense of $3.4 million for the three months ended December 31, 2023 . Research and development expenses totaled $27.7 million for the three months ended December 31, 2024 , compared to $36.4 million for the three months ended December 31, 2023 . The decrease was due to a decrease in expenses for Enanta’s virology program due to timing of clinical trials in the company’s RSV program and to a lesser extent, a decrease in costs associated with Enanta’s COVID-19 program, as the company previously announced any further COVID-19 efforts would be in the context of collaborations. General and administrative expenses totaled $12.8 million for the three months ended December 31, 2024 , compared to $16.5 million for the three months ended December 31, 2023 . The decrease was due to a decrease in legal expenses related to the company’s patent infringement lawsuit against Pfizer. Interest and investment income, net, totaled $2.8 million for the three months ended December 31, 2024 , compared to $4.3 million for the three months ended December 31, 2023 . The decrease was due to lower cash and investment balances year-over-year. Enanta recorded an income tax benefit of $0.4 million for the three months ended December 31, 2024 , and $0.6 million for the three months ended December 31, 2023 . The income tax benefit in both periods was driven by interest earned on a pending $28 million federal income tax refund. Net loss for the three months ended December 31, 2024 was $22.3 million , or a loss of $1.05 per diluted common share, compared to a net loss of $33.4 million , or a loss of $1.58 per diluted common share, for the corresponding period in 2023. Enanta’s cash, cash equivalents and short-term marketable securities totaled $216.7 million at December 31, 2024 . Enanta expects that its current cash, cash equivalents and marketable securities, as well as its retained portion of future royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs into fiscal year 2028. Virology RSV Enanta aims to develop a first and leading RSV antiviral treatment portfolio to help all populations at high-risk for severe outcomes from RSV infection. This includes zelicapavir, Enanta’s lead, oral N-protein inhibitor, and EDP-323, its oral L-protein inhibitor, both of which received Fast Track designation from the U.S. Food and Drug Administration . Zelicapavir is being evaluated in RSVHR, a Phase 2b, randomized, double-blind, placebo-controlled study in adults with RSV infection who are at high risk of complications, including age over 65 years and/or those with congestive heart failure, chronic obstructive pulmonary disease or asthma. Enrollment in RSVHR is progressing, and the company is targeting completion in the current Northern Hemisphere RSV season with topline data in the third quarter of 2025. In December 2024 , Enanta announced results from a Phase 2 randomized, double-blind, placebo-controlled study in hospitalized and non-hospitalized pediatric RSV patients aged 28 days to 3 years old. In the study of 96 patients, an antiviral effect was observed for the primary and secondary virology endpoints in the overall pooled efficacy population. The primary endpoint in Part 2 of the study, which focused on virology, showed a pronounced antiviral effect with a 1.4 log decline in viral load at Day 5 compared to placebo. Additionally, a rapid and robust virologic effect was observed in a prespecified subset of patients who were randomized within 3 days of symptom onset, with a 1.2 log decline in viral load at Day 5 compared to placebo. The study also showed that zelicapavir demonstrated a favorable safety profile and was well-tolerated in this pediatric population. Enanta’s second clinical RSV candidate, EDP-323, is a novel oral, direct-acting antiviral selectively targeting the RSV L-protein. In September 2024 , Enanta announced positive results for EDP-323 in a Phase 2a challenge study of healthy adults infected with RSV, in which treatment with EDP-323 achieved highly statistically significant reductions in both viral load and clinical symptoms compared to placebo, as well as demonstrated a favorable safety and tolerability profile. With positive results from both zelicapavir and EDP-323, Enanta has the most advanced portfolio of RSV therapeutic candidates, which provides important optionality and the potential for first-in-disease and best-in-disease development strategies. The company expects to work with regulators to align on the registration pathway for zelicapavir in pediatric patients and will look to complete RSVHR, a Phase 3 enabling trial in high-risk adults. In addition, Enanta will evaluate potential partnership opportunities to advance its RSV assets to the next stage of clinical development. Zelicapavir is being evaluated in RSVHR, a Phase 2b, randomized, double-blind, placebo-controlled study in adults with RSV infection who are at high risk of complications, including age over 65 years and/or those with congestive heart failure, chronic obstructive pulmonary disease or asthma. Enrollment in RSVHR is progressing, and the company is targeting completion in the current Northern Hemisphere RSV season with topline data in the third quarter of 2025. In December 2024 , Enanta announced results from a Phase 2 randomized, double-blind, placebo-controlled study in hospitalized and non-hospitalized pediatric RSV patients aged 28 days to 3 years old. In the study of 96 patients, an antiviral effect was observed for the primary and secondary virology endpoints in the overall pooled efficacy population. The primary endpoint in Part 2 of the study, which focused on virology, showed a pronounced antiviral effect with a 1.4 log decline in viral load at Day 5 compared to placebo. Additionally, a rapid and robust virologic effect was observed in a prespecified subset of patients who were randomized within 3 days of symptom onset, with a 1.2 log decline in viral load at Day 5 compared to placebo. The study also showed that zelicapavir demonstrated a favorable safety profile and was well-tolerated in this pediatric population. Enanta’s second clinical RSV candidate, EDP-323, is a novel oral, direct-acting antiviral selectively targeting the RSV L-protein. In September 2024 , Enanta announced positive results for EDP-323 in a Phase 2a challenge study of healthy adults infected with RSV, in which treatment with EDP-323 achieved highly statistically significant reductions in both viral load and clinical symptoms compared to placebo, as well as demonstrated a favorable safety and tolerability profile. With positive results from both zelicapavir and EDP-323, Enanta has the most advanced portfolio of RSV therapeutic candidates, which provides important optionality and the potential for first-in-disease and best-in-disease development strategies. The company expects to work with regulators to align on the registration pathway for zelicapavir in pediatric patients and will look to complete RSVHR, a Phase 3 enabling trial in high-risk adults. In addition, Enanta will evaluate potential partnership opportunities to advance its RSV assets to the next stage of clinical development. In December 2024 , Enanta announced results from a Phase 2 randomized, double-blind, placebo-controlled study in hospitalized and non-hospitalized pediatric RSV patients aged 28 days to 3 years old. In the study of 96 patients, an antiviral effect was observed for the primary and secondary virology endpoints in the overall pooled efficacy population. The primary endpoint in Part 2 of the study, which focused on virology, showed a pronounced antiviral effect with a 1.4 log decline in viral load at Day 5 compared to placebo. Additionally, a rapid and robust virologic effect was observed in a prespecified subset of patients who were randomized within 3 days of symptom onset, with a 1.2 log decline in viral load at Day 5 compared to placebo. The study also showed that zelicapavir demonstrated a favorable safety profile and was well-tolerated in this pediatric population. Immunology Enanta’s immunology portfolio is focused on designing and developing highly potent and selective, oral small molecule inhibitors for the treatment of inflammatory diseases, by targeting key drivers of the type 2 immune response. KIT Inhibitors: EPS-1421, Enanta’s lead candidate, is a novel, potent and selective oral inhibitor of KIT, designed to treat chronic spontaneous urticaria and other indications by depleting mast cells, thereby addressing a primary driver of these diseases. EPS-1421 inhibits KIT with nanomolar potency in both binding and cellular assays, and has sub-nanomolar activity in vivo. EPS-1421 is also highly selective for KIT versus other kinases and, preclinically, has demonstrated good in vitro and in vivo ADME properties. Enanta is conducting scale-up activities and IND enabling studies in 2025. STAT6 Inhibitors: Enanta is advancing novel, potent and selective oral inhibitors of STAT6 for the treatment of type 2 immune driven diseases. The company will initially focus on atopic dermatitis and expand into other indications that block the IL-4/IL-13 signaling pathway, thereby addressing a primary driver of these diseases. Enanta’s prototype inhibitors demonstrate potent activity and high selectivity for STAT6 over other STATs in both biochemical and cellular assays. Additionally, the prototype inhibitors demonstrate systemic in vivo target engagement after ex vivo IL-4 stimulation. The company is conducting lead optimization activities and plans to select a STAT6 lead candidate in the second half of 2025. Enanta plans to expand its presence in immunology with the introduction of a third program in 2025. KIT Inhibitors: EPS-1421, Enanta’s lead candidate, is a novel, potent and selective oral inhibitor of KIT, designed to treat chronic spontaneous urticaria and other indications by depleting mast cells, thereby addressing a primary driver of these diseases. EPS-1421 inhibits KIT with nanomolar potency in both binding and cellular assays, and has sub-nanomolar activity in vivo. EPS-1421 is also highly selective for KIT versus other kinases and, preclinically, has demonstrated good in vitro and in vivo ADME properties. Enanta is conducting scale-up activities and IND enabling studies in 2025. STAT6 Inhibitors: Enanta is advancing novel, potent and selective oral inhibitors of STAT6 for the treatment of type 2 immune driven diseases. The company will initially focus on atopic dermatitis and expand into other indications that block the IL-4/IL-13 signaling pathway, thereby addressing a primary driver of these diseases. Enanta’s prototype inhibitors demonstrate potent activity and high selectivity for STAT6 over other STATs in both biochemical and cellular assays. Additionally, the prototype inhibitors demonstrate systemic in vivo target engagement after ex vivo IL-4 stimulation. The company is conducting lead optimization activities and plans to select a STAT6 lead candidate in the second half of 2025. Enanta plans to expand its presence in immunology with the introduction of a third program in 2025. EPS-1421, Enanta’s lead candidate, is a novel, potent and selective oral inhibitor of KIT, designed to treat chronic spontaneous urticaria and other indications by depleting mast cells, thereby addressing a primary driver of these diseases. EPS-1421 inhibits KIT with nanomolar potency in both binding and cellular assays, and has sub-nanomolar activity in vivo. EPS-1421 is also highly selective for KIT versus other kinases and, preclinically, has demonstrated good in vitro and in vivo ADME properties. Enanta is conducting scale-up activities and IND enabling studies in 2025. Enanta is advancing novel, potent and selective oral inhibitors of STAT6 for the treatment of type 2 immune driven diseases. The company will initially focus on atopic dermatitis and expand into other indications that block the IL-4/IL-13 signaling pathway, thereby addressing a primary driver of these diseases. Enanta’s prototype inhibitors demonstrate potent activity and high selectivity for STAT6 over other STATs in both biochemical and cellular assays. Additionally, the prototype inhibitors demonstrate systemic in vivo target engagement after ex vivo IL-4 stimulation. The company is conducting lead optimization activities and plans to select a STAT6 lead candidate in the second half of 2025. Corporate On February 3, 2025 , Enanta filed a notice of appeal with the United States Court of Appeals for the Federal Circuit related to a June 2022 lawsuit the company filed in the United States District Court for the District of Massachusetts against Pfizer, Inc. seeking damages for infringement of U.S. Patent No. 11,358,953 (the ’953 Patent) in the manufacture, use and sale of Pfizer’s COVID-19 antiviral, Paxlovid™ (nirmatrelvir tablets; ritonavir tablets). Enanta plans to issue its fiscal second quarter financial results press release on May 12, 2025 . About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® ( U.S. ) and MAVIRET® (ex- U.S. ) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information. Forward Looking Statements This press release contains forward-looking statements, including statements with respect to the prospects for advancement of Enanta’s clinical programs in RSV and its preclinical programs targeting KIT and STAT6 inhibition. Statements that are not historical facts are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and the industry in which it operates and management’s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: the impact of development, regulatory and marketing efforts of others with respect to vaccines and competitive treatments for RSV; the discovery and development risks of Enanta’s programs in virology and immunology; Enanta’s lack of clinical development experience; Enanta’s need to attract and retain senior management and key research and development personnel; Enanta’s need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in “Risk Factors” in Enanta’s Form 10-K for the fiscal year-ended September 30, 2024 , and any other periodic reports filed more recently with the Securities and Exchange Commission . Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law. Tables to Follow 2024 2023 $ 16,959 $ 18,003 27,656 36,371 12,846 16,518 40,502 52,889 (23,543 ) (34,886 ) (1,962 ) (3,441 ) 2,799 4,298 (22,706 ) (34,029 ) 416 622 $ (22,290 ) $ (33,407 ) $ (1.05 ) $ (1.58 ) $ (1.05 ) $ (1.58 ) 21,238 21,088 21,238 21,088 2024 2024 $ 84,349 $ 37,233 132,342 210,953 7,718 6,646 10,684 12,413 32,444 31,999 608 608 268,145 299,852 37,368 32,688 39,675 40,658 3,360 3,360 94 94 $ 348,642 $ 376,652 $ 4,726 $ 8,002 10,575 13,547 32,743 34,462 1,006 1,524 49,050 57,535 129,738 134,779 56,453 53,943 1,350 1,350 235 231 236,826 247,838 111,816 128,814 $ 348,642 $ 376,652 View source version on businesswire.com: https://www.businesswire.com/news/home/20250210108421/en/ Media and Investors Contact: Jennifer Viera jviera@enanta.com Source: Enanta Pharmaceuticals, Inc.